Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 9Terminated 5Recruiting 5Unknown 4Withdrawn 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 43Stomach Neoplasms 42Rectal Neoplasms 28Pancreatic Neoplasms 16Lymphoma, Large B-Cell, Diffuse 13Colonic Neoplasms 13Cholangiocarcinoma 11Neoplasm Metastasis 10Adenocarcinoma 10Neoplasms 9Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 7Biliary Tract Neoplasms 7Locally Advanced Rectal Cancer 6Gastrointestinal Neoplasms 6Gallbladder Neoplasms 6Esophageal Neoplasms 6Adenocarcinoma Of Esophagus 6Recurrence 5Peritoneal Neoplasms 5Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 3Carcinoma 3Bile Duct Neoplasms 3Appendiceal Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Pathologic Complete Response 2Melanoma 2Lymphoma, Non-Hodgkin 2

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Oxaliplatin × Clear all
NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04984837 2026-04-20

Study of Lacutamab in Peripheral T-cell Lymphoma

The Lymphoma Academic Research Organisation

Phase 2 Recruiting
56 enrolled
Lymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Fudan University

Phase 2 Recruiting
130 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05476796 2024-10-24

LOGICAN

UNICANCER

Phase 2 Recruiting
118 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT02889666 2024-04-17

CCODG-NSCLC

Shanghai Jiao Tong University School of Medicine

Phase 1 Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡